Replimune Secures $150M Capital Raise at Premium Following FDA Approval
REPL has more than doubled off its 52-week low of $1.5.
Summary
Replimune announced a $150 million underwritten offering of common stock and pre-funded warrants, priced at a premium to the current market, securing vital capital after its recent FDA product approval and prior "going concern" warning.
Key Events · Financing and Capital Events · REPL
-
Capital Raise Details
Replimune priced an underwritten offering of 9,701,490 shares of common stock and pre-funded warrants to purchase 2,736,340 shares, totaling 12,437,830 shares (common + underlying warrants).
-
Significant Proceeds
The offering is expected to generate approximately $140.5 million in net proceeds, providing crucial funding for the company.
-
Premium Pricing
Shares and pre-funded warrants were priced at $12.06 and $12.0599 respectively, which is above the current market price of $11.69.
-
Strategic Timing Post-FDA Approval
This financing follows closely on the heels of the FDA's accelerated approval of TUDRIQEV, Replimune's first commercial product, addressing prior "going concern" warnings and extending the cash runway.
Analysis · REPL · Life Sciences
This significant capital raise provides critical funding for Replimune, which previously reported a "going concern" warning and limited cash runway. The offering, priced at a premium to the current market price, comes just days after the company received FDA accelerated approval for its first commercial product, TUDRIQEV. This indicates strong institutional confidence and provides the necessary resources for commercialization and continued operations.
At the time of this filing, REPL was trading at $11.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $1.50 to $13.90. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.